• To date more than different mutations

  2024-11-19

  

  To date, more than 50 different mutations in the gene have been described (Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff: SRD5A2 Gene: http://www.hgmd.cf.ac.uk). Most of them are missense mutations but premature stop codons and deletions leading to non-functional or su

• Over the past decade extensive research has been directed to

  2024-11-19

  

  Over the past decade, extensive research has been directed toward the discovery of Aurora-selective small-molecule inhibitors. As a result, a handful of Aurora inhibitors has been identified. Among them, 1 (VX-680) and 2 (SNS-314) have entered human clinical trials as pan-Aurora kinase inhibitors (F

• Demonstration of in vivo efficacy of potential chemopreventi

  2024-11-19

  

  Demonstration of in vivo efficacy of potential chemopreventive agents in animal models is necessary for their clinical development. Our present study provides experimental evidence that CuB 0.1μmol by oral administration (for 2weeks before the cancer cell injection, 5days per week) significantly inh

• SMI-4a The evidence points toward a role for LO

  2024-11-19

  

  The evidence points toward a role for 12/15-LO activity in WAT in modulating chronic local inflammation and subsequent systemic metabolic decline in the obese state. However, little is known as to the role of 12- and 15-LOs in BAT. Indeed, in addition to WAT, platelet- and leukocyte-type 12-LO are e

• Regulators of the DDR have therefore become attractive targe

  2024-11-19

  

  Regulators of the DDR have therefore become attractive targets for cancer therapy primarily through two potential approaches. First, to be used as chemo- or radiosensitisers to increase the effectiveness of standard genotoxic treatments and to help prevent or overcome the development of resistance.

• br Materials and methods br

  2024-11-19

  

  Materials and methods Results Discussion Because the Ser/Thr kinase domain of LRRK2 is homologous to that of other MLK family proteins belonging to the MAP3K superfamily, LRRK2 is suggested to be involved in MAPK signaling and activation of neuronal cell death by phosphorylating its downstr

• Knowledge about adipose tissue has

  2024-11-19

  

  Knowledge about adipose tissue has evolved considerably over the last two decades. Always been described as an inert tissue having the function of stocking lipids, adipose tissue is now recognized as a real organ with both metabolic and endocrine functions secreting various factors into the blood to

• Besides Arg overexpression our data revealed that AGEs

  2024-11-19

  

  Besides Arg2 overexpression, our data revealed that AGEs could decrease eNOS mRNA levels, which is considered a significant cause for attenuated NO production and vasodilation. It was found recently that AGEs significantly reduce eNOS expression levels and NO bioavailability in human carotid artery

• br Introduction Sustained over activation of neurohormonal

  2024-11-19

  

  Introduction Sustained over-activation of neurohormonal systems is a hallmark in the pathophysiology of cardiac dysfunction following myocardial infarction (MI) and heart failure (HF). Inhibitors of the renin-angiotensin STING pathway activator system (RAAS) constitute cornerstones of pharmacothe

• Based on the general structure function principle in

  2024-11-18

  

  Based on the general structure-function principle in biology [[19], [20], [21]], toxic oligomers are expected to have well-defined three-dimensional structures to carry out their pathological functions. A common amyloid toxicity mechanism also suggests that toxic oligomers of different amyloid prote

• Dose Response Studies Against Puromycin

  2024-11-18

  

  Dose–Response Studies Against Puromycin–Sensitive Aminopeptidase (PSA). PSA is a ubiquitous metallopeptidase encoded by the NPEPPS gene with subcellular distribution in the cytosol and nucleus [49]. Comprising of a 919 amino Ki16198 sequence, it has a broad substrate specificity, and is responsible

• br Neurological development and BCAAs

  2024-11-18

  

  Neurological development and BCAAs Glutamate is an important excitatory neurotransmitter in the brain, and BCAAs (especially leucine) function to synthesize glutamate in astrocytes around neurons, since leucine enters the brain from the blood more rapidly than other gaba receptors and provides ∼

• br Development of lorlatinib from crizotinib to

  2024-11-18

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Interestingly intermittent high doses of AKT inhibitors

  2024-11-18

  

  Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particula

• Further evidence for action mechanism was provided by assays

  2024-11-18

  

  Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t

16008 records 61/1068 page Previous Next First page 上5页 6162636465 下5页 Last page